nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—Dacarbazine—melanoma	0.407	1	CbGbCtD
Dicyclomine—Paralysis—Vemurafenib—melanoma	0.0111	0.0314	CcSEcCtD
Dicyclomine—Thrombosis—Carmustine—melanoma	0.00576	0.0163	CcSEcCtD
Dicyclomine—Necrosis—Dactinomycin—melanoma	0.00555	0.0157	CcSEcCtD
Dicyclomine—Necrosis—Carmustine—melanoma	0.00519	0.0147	CcSEcCtD
Dicyclomine—Speech disorder—Carmustine—melanoma	0.00474	0.0134	CcSEcCtD
Dicyclomine—Speech disorder—Temozolomide—melanoma	0.00458	0.013	CcSEcCtD
Dicyclomine—Injection site reaction—Carmustine—melanoma	0.00405	0.0115	CcSEcCtD
Dicyclomine—Disorientation—Bleomycin—melanoma	0.00379	0.0107	CcSEcCtD
Dicyclomine—Eye disorder—Vemurafenib—melanoma	0.00362	0.0102	CcSEcCtD
Dicyclomine—Cardiac disorder—Vemurafenib—melanoma	0.00359	0.0102	CcSEcCtD
Dicyclomine—Dermatitis atopic—Docetaxel—melanoma	0.00354	0.01	CcSEcCtD
Dicyclomine—Mediastinal disorder—Vemurafenib—melanoma	0.00349	0.00987	CcSEcCtD
Dicyclomine—Thrombophlebitis—Carmustine—melanoma	0.00342	0.00967	CcSEcCtD
Dicyclomine—Erythema—Vemurafenib—melanoma	0.00337	0.00953	CcSEcCtD
Dicyclomine—Necrosis—Docetaxel—melanoma	0.00334	0.00944	CcSEcCtD
Dicyclomine—Thrombophlebitis—Temozolomide—melanoma	0.0033	0.00935	CcSEcCtD
Dicyclomine—Ageusia—Docetaxel—melanoma	0.00323	0.00915	CcSEcCtD
Dicyclomine—Lethargy—Dactinomycin—melanoma	0.00322	0.00913	CcSEcCtD
Dicyclomine—Amnesia—Carmustine—melanoma	0.00315	0.00891	CcSEcCtD
Dicyclomine—Nasal congestion—Temozolomide—melanoma	0.00314	0.00888	CcSEcCtD
Dicyclomine—Amnesia—Temozolomide—melanoma	0.00304	0.00861	CcSEcCtD
Dicyclomine—Diplopia—Carmustine—melanoma	0.00296	0.00837	CcSEcCtD
Dicyclomine—Diplopia—Temozolomide—melanoma	0.00286	0.00809	CcSEcCtD
Dicyclomine—Face oedema—Carmustine—melanoma	0.00286	0.00808	CcSEcCtD
Dicyclomine—Affect lability—Temozolomide—melanoma	0.00281	0.00796	CcSEcCtD
Dicyclomine—Face oedema—Temozolomide—melanoma	0.00276	0.00781	CcSEcCtD
Dicyclomine—Anaphylactic shock—Vemurafenib—melanoma	0.00275	0.00778	CcSEcCtD
Dicyclomine—Mood swings—Temozolomide—melanoma	0.00271	0.00766	CcSEcCtD
Dicyclomine—Nervous system disorder—Vemurafenib—melanoma	0.0027	0.00763	CcSEcCtD
Dicyclomine—Muscular weakness—Carmustine—melanoma	0.00261	0.00738	CcSEcCtD
Dicyclomine—Injection site reaction—Docetaxel—melanoma	0.0026	0.00737	CcSEcCtD
Dicyclomine—Breast disorder—Temozolomide—melanoma	0.00258	0.00731	CcSEcCtD
Dicyclomine—Muscular weakness—Temozolomide—melanoma	0.00252	0.00714	CcSEcCtD
Dicyclomine—Abdominal distension—Temozolomide—melanoma	0.00249	0.00704	CcSEcCtD
Dicyclomine—Decreased appetite—Vemurafenib—melanoma	0.00239	0.00676	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00237	0.00672	CcSEcCtD
Dicyclomine—Fatigue—Vemurafenib—melanoma	0.00237	0.00671	CcSEcCtD
Dicyclomine—Constipation—Vemurafenib—melanoma	0.00235	0.00665	CcSEcCtD
Dicyclomine—Lightheadedness—Docetaxel—melanoma	0.00234	0.00663	CcSEcCtD
Dicyclomine—Hypoaesthesia—Bleomycin—melanoma	0.00233	0.0066	CcSEcCtD
Dicyclomine—Erectile dysfunction—Temozolomide—melanoma	0.00228	0.00644	CcSEcCtD
Dicyclomine—Thrombophlebitis—Docetaxel—melanoma	0.0022	0.00622	CcSEcCtD
Dicyclomine—Erythema—Bleomycin—melanoma	0.00204	0.00578	CcSEcCtD
Dicyclomine—Hallucination—Carmustine—melanoma	0.00204	0.00576	CcSEcCtD
Dicyclomine—Hypoaesthesia—Carmustine—melanoma	0.00204	0.00576	CcSEcCtD
Dicyclomine—Hypersensitivity—Vemurafenib—melanoma	0.00203	0.00573	CcSEcCtD
Dicyclomine—Asthenia—Vemurafenib—melanoma	0.00197	0.00558	CcSEcCtD
Dicyclomine—Hallucination—Temozolomide—melanoma	0.00197	0.00557	CcSEcCtD
Dicyclomine—Hypoaesthesia—Temozolomide—melanoma	0.00197	0.00557	CcSEcCtD
Dicyclomine—Pruritus—Vemurafenib—melanoma	0.00194	0.0055	CcSEcCtD
Dicyclomine—Lethargy—Docetaxel—melanoma	0.00194	0.00549	CcSEcCtD
Dicyclomine—Eye disorder—Carmustine—melanoma	0.00191	0.00541	CcSEcCtD
Dicyclomine—Erythema—Dactinomycin—melanoma	0.0019	0.00539	CcSEcCtD
Dicyclomine—Ill-defined disorder—Bleomycin—melanoma	0.00189	0.00536	CcSEcCtD
Dicyclomine—Eye disorder—Temozolomide—melanoma	0.00185	0.00523	CcSEcCtD
Dicyclomine—Malaise—Bleomycin—melanoma	0.00184	0.00521	CcSEcCtD
Dicyclomine—Cardiac disorder—Temozolomide—melanoma	0.00184	0.00519	CcSEcCtD
Dicyclomine—Dizziness—Vemurafenib—melanoma	0.00182	0.00515	CcSEcCtD
Dicyclomine—Mental disorder—Carmustine—melanoma	0.00179	0.00507	CcSEcCtD
Dicyclomine—Immune system disorder—Temozolomide—melanoma	0.00179	0.00506	CcSEcCtD
Dicyclomine—Mediastinal disorder—Temozolomide—melanoma	0.00178	0.00504	CcSEcCtD
Dicyclomine—Erythema—Carmustine—melanoma	0.00178	0.00504	CcSEcCtD
Dicyclomine—Ill-defined disorder—Dactinomycin—melanoma	0.00177	0.005	CcSEcCtD
Dicyclomine—Vomiting—Vemurafenib—melanoma	0.00175	0.00495	CcSEcCtD
Dicyclomine—Rash—Vemurafenib—melanoma	0.00173	0.00491	CcSEcCtD
Dicyclomine—Mental disorder—Temozolomide—melanoma	0.00173	0.0049	CcSEcCtD
Dicyclomine—Dermatitis—Vemurafenib—melanoma	0.00173	0.0049	CcSEcCtD
Dicyclomine—Headache—Vemurafenib—melanoma	0.00172	0.00487	CcSEcCtD
Dicyclomine—Erythema—Temozolomide—melanoma	0.00172	0.00487	CcSEcCtD
Dicyclomine—Breast disorder—Docetaxel—melanoma	0.00172	0.00486	CcSEcCtD
Dicyclomine—Discomfort—Bleomycin—melanoma	0.00172	0.00486	CcSEcCtD
Dicyclomine—Malaise—Dactinomycin—melanoma	0.00172	0.00486	CcSEcCtD
Dicyclomine—Confusional state—Bleomycin—melanoma	0.00168	0.00475	CcSEcCtD
Dicyclomine—Vision blurred—Carmustine—melanoma	0.00168	0.00475	CcSEcCtD
Dicyclomine—Anaphylactic shock—Bleomycin—melanoma	0.00167	0.00471	CcSEcCtD
Dicyclomine—Oedema—Bleomycin—melanoma	0.00167	0.00471	CcSEcCtD
Dicyclomine—Agitation—Carmustine—melanoma	0.00164	0.00463	CcSEcCtD
Dicyclomine—Nausea—Vemurafenib—melanoma	0.00163	0.00462	CcSEcCtD
Dicyclomine—Vision blurred—Temozolomide—melanoma	0.00162	0.00459	CcSEcCtD
Dicyclomine—Discomfort—Dactinomycin—melanoma	0.0016	0.00453	CcSEcCtD
Dicyclomine—Ill-defined disorder—Temozolomide—melanoma	0.0016	0.00452	CcSEcCtD
Dicyclomine—Anorexia—Bleomycin—melanoma	0.00159	0.00449	CcSEcCtD
Dicyclomine—Agitation—Temozolomide—melanoma	0.00158	0.00448	CcSEcCtD
Dicyclomine—Angioedema—Temozolomide—melanoma	0.00157	0.00445	CcSEcCtD
Dicyclomine—Oedema—Dactinomycin—melanoma	0.00155	0.0044	CcSEcCtD
Dicyclomine—Malaise—Temozolomide—melanoma	0.00155	0.00439	CcSEcCtD
Dicyclomine—Hypertension—Carmustine—melanoma	0.00154	0.00435	CcSEcCtD
Dicyclomine—Palpitations—Temozolomide—melanoma	0.00152	0.00431	CcSEcCtD
Dicyclomine—Paraesthesia—Bleomycin—melanoma	0.0015	0.00423	CcSEcCtD
Dicyclomine—Hypertension—Temozolomide—melanoma	0.00149	0.00421	CcSEcCtD
Dicyclomine—Dyspnoea—Bleomycin—melanoma	0.00148	0.0042	CcSEcCtD
Dicyclomine—Anorexia—Dactinomycin—melanoma	0.00148	0.00419	CcSEcCtD
Dicyclomine—Confusional state—Carmustine—melanoma	0.00147	0.00415	CcSEcCtD
Dicyclomine—Oedema—Carmustine—melanoma	0.00145	0.00411	CcSEcCtD
Dicyclomine—Discomfort—Temozolomide—melanoma	0.00145	0.0041	CcSEcCtD
Dicyclomine—Decreased appetite—Bleomycin—melanoma	0.00145	0.0041	CcSEcCtD
Dicyclomine—Dry mouth—Temozolomide—melanoma	0.00143	0.00406	CcSEcCtD
Dicyclomine—Pain—Bleomycin—melanoma	0.00142	0.00403	CcSEcCtD
Dicyclomine—Tachycardia—Carmustine—melanoma	0.00142	0.00402	CcSEcCtD
Dicyclomine—Confusional state—Temozolomide—melanoma	0.00142	0.00401	CcSEcCtD
Dicyclomine—Anaphylactic shock—Temozolomide—melanoma	0.0014	0.00398	CcSEcCtD
Dicyclomine—Oedema—Temozolomide—melanoma	0.0014	0.00398	CcSEcCtD
Dicyclomine—Anorexia—Carmustine—melanoma	0.00139	0.00392	CcSEcCtD
Dicyclomine—Nervous system disorder—Temozolomide—melanoma	0.00138	0.0039	CcSEcCtD
Dicyclomine—Feeling abnormal—Bleomycin—melanoma	0.00137	0.00388	CcSEcCtD
Dicyclomine—Decreased appetite—Dactinomycin—melanoma	0.00135	0.00382	CcSEcCtD
Dicyclomine—Fatigue—Dactinomycin—melanoma	0.00134	0.00379	CcSEcCtD
Dicyclomine—Anorexia—Temozolomide—melanoma	0.00134	0.00379	CcSEcCtD
Dicyclomine—Pain—Dactinomycin—melanoma	0.00133	0.00376	CcSEcCtD
Dicyclomine—Urticaria—Bleomycin—melanoma	0.00132	0.00374	CcSEcCtD
Dicyclomine—Insomnia—Carmustine—melanoma	0.00131	0.00372	CcSEcCtD
Dicyclomine—Hypoaesthesia—Docetaxel—melanoma	0.00131	0.0037	CcSEcCtD
Dicyclomine—Paraesthesia—Carmustine—melanoma	0.00131	0.00369	CcSEcCtD
Dicyclomine—Dyspnoea—Carmustine—melanoma	0.0013	0.00367	CcSEcCtD
Dicyclomine—Somnolence—Carmustine—melanoma	0.00129	0.00366	CcSEcCtD
Dicyclomine—Feeling abnormal—Dactinomycin—melanoma	0.00128	0.00362	CcSEcCtD
Dicyclomine—Insomnia—Temozolomide—melanoma	0.00127	0.0036	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Dactinomycin—melanoma	0.00127	0.0036	CcSEcCtD
Dicyclomine—Decreased appetite—Carmustine—melanoma	0.00126	0.00358	CcSEcCtD
Dicyclomine—Paraesthesia—Temozolomide—melanoma	0.00126	0.00357	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Carmustine—melanoma	0.00126	0.00355	CcSEcCtD
Dicyclomine—Dyspnoea—Temozolomide—melanoma	0.00125	0.00355	CcSEcCtD
Dicyclomine—Somnolence—Temozolomide—melanoma	0.00125	0.00354	CcSEcCtD
Dicyclomine—Constipation—Carmustine—melanoma	0.00124	0.00352	CcSEcCtD
Dicyclomine—Pain—Carmustine—melanoma	0.00124	0.00352	CcSEcCtD
Dicyclomine—Dyspepsia—Temozolomide—melanoma	0.00124	0.0035	CcSEcCtD
Dicyclomine—Eye disorder—Docetaxel—melanoma	0.00123	0.00348	CcSEcCtD
Dicyclomine—Abdominal pain—Dactinomycin—melanoma	0.00123	0.00348	CcSEcCtD
Dicyclomine—Hypersensitivity—Bleomycin—melanoma	0.00123	0.00347	CcSEcCtD
Dicyclomine—Decreased appetite—Temozolomide—melanoma	0.00122	0.00346	CcSEcCtD
Dicyclomine—Cardiac disorder—Docetaxel—melanoma	0.00122	0.00345	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Temozolomide—melanoma	0.00121	0.00343	CcSEcCtD
Dicyclomine—Fatigue—Temozolomide—melanoma	0.00121	0.00343	CcSEcCtD
Dicyclomine—Pain—Temozolomide—melanoma	0.0012	0.0034	CcSEcCtD
Dicyclomine—Constipation—Temozolomide—melanoma	0.0012	0.0034	CcSEcCtD
Dicyclomine—Feeling abnormal—Carmustine—melanoma	0.0012	0.00339	CcSEcCtD
Dicyclomine—Asthenia—Bleomycin—melanoma	0.00119	0.00338	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Carmustine—melanoma	0.00119	0.00336	CcSEcCtD
Dicyclomine—Immune system disorder—Docetaxel—melanoma	0.00119	0.00336	CcSEcCtD
Dicyclomine—Mediastinal disorder—Docetaxel—melanoma	0.00119	0.00335	CcSEcCtD
Dicyclomine—Pruritus—Bleomycin—melanoma	0.00118	0.00334	CcSEcCtD
Dicyclomine—Feeling abnormal—Temozolomide—melanoma	0.00116	0.00328	CcSEcCtD
Dicyclomine—Mental disorder—Docetaxel—melanoma	0.00115	0.00326	CcSEcCtD
Dicyclomine—Abdominal pain—Carmustine—melanoma	0.00115	0.00325	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Temozolomide—melanoma	0.00115	0.00325	CcSEcCtD
Dicyclomine—Erythema—Docetaxel—melanoma	0.00114	0.00324	CcSEcCtD
Dicyclomine—Hypersensitivity—Dactinomycin—melanoma	0.00114	0.00324	CcSEcCtD
Dicyclomine—Urticaria—Temozolomide—melanoma	0.00112	0.00316	CcSEcCtD
Dicyclomine—Asthenia—Dactinomycin—melanoma	0.00111	0.00315	CcSEcCtD
Dicyclomine—Abdominal pain—Temozolomide—melanoma	0.00111	0.00314	CcSEcCtD
Dicyclomine—Hypersensitivity—Carmustine—melanoma	0.00107	0.00303	CcSEcCtD
Dicyclomine—Vomiting—Bleomycin—melanoma	0.00106	0.003	CcSEcCtD
Dicyclomine—Rash—Bleomycin—melanoma	0.00105	0.00297	CcSEcCtD
Dicyclomine—Dermatitis—Bleomycin—melanoma	0.00105	0.00297	CcSEcCtD
Dicyclomine—Asthenia—Carmustine—melanoma	0.00104	0.00295	CcSEcCtD
Dicyclomine—Hypersensitivity—Temozolomide—melanoma	0.00104	0.00293	CcSEcCtD
Dicyclomine—Syncope—Docetaxel—melanoma	0.00103	0.00291	CcSEcCtD
Dicyclomine—Palpitations—Docetaxel—melanoma	0.00101	0.00286	CcSEcCtD
Dicyclomine—Asthenia—Temozolomide—melanoma	0.00101	0.00285	CcSEcCtD
Dicyclomine—Loss of consciousness—Docetaxel—melanoma	0.00101	0.00285	CcSEcCtD
Dicyclomine—Pruritus—Temozolomide—melanoma	0.000994	0.00281	CcSEcCtD
Dicyclomine—Nausea—Bleomycin—melanoma	0.000989	0.0028	CcSEcCtD
Dicyclomine—Hypertension—Docetaxel—melanoma	0.000988	0.0028	CcSEcCtD
Dicyclomine—Vomiting—Dactinomycin—melanoma	0.000988	0.0028	CcSEcCtD
Dicyclomine—Rash—Dactinomycin—melanoma	0.000979	0.00277	CcSEcCtD
Dicyclomine—Dizziness—Carmustine—melanoma	0.000961	0.00272	CcSEcCtD
Dicyclomine—Dry mouth—Docetaxel—melanoma	0.000953	0.0027	CcSEcCtD
Dicyclomine—Confusional state—Docetaxel—melanoma	0.000942	0.00267	CcSEcCtD
Dicyclomine—Oedema—Docetaxel—melanoma	0.000934	0.00264	CcSEcCtD
Dicyclomine—Anaphylactic shock—Docetaxel—melanoma	0.000934	0.00264	CcSEcCtD
Dicyclomine—Dizziness—Temozolomide—melanoma	0.000929	0.00263	CcSEcCtD
Dicyclomine—Vomiting—Carmustine—melanoma	0.000924	0.00262	CcSEcCtD
Dicyclomine—Nausea—Dactinomycin—melanoma	0.000923	0.00261	CcSEcCtD
Dicyclomine—Shock—Docetaxel—melanoma	0.000919	0.0026	CcSEcCtD
Dicyclomine—Rash—Carmustine—melanoma	0.000917	0.00259	CcSEcCtD
Dicyclomine—Nervous system disorder—Docetaxel—melanoma	0.000916	0.00259	CcSEcCtD
Dicyclomine—Dermatitis—Carmustine—melanoma	0.000916	0.00259	CcSEcCtD
Dicyclomine—Tachycardia—Docetaxel—melanoma	0.000912	0.00258	CcSEcCtD
Dicyclomine—Headache—Carmustine—melanoma	0.000911	0.00258	CcSEcCtD
Dicyclomine—Vomiting—Temozolomide—melanoma	0.000893	0.00253	CcSEcCtD
Dicyclomine—Anorexia—Docetaxel—melanoma	0.000891	0.00252	CcSEcCtD
Dicyclomine—Rash—Temozolomide—melanoma	0.000886	0.00251	CcSEcCtD
Dicyclomine—Dermatitis—Temozolomide—melanoma	0.000885	0.0025	CcSEcCtD
Dicyclomine—Headache—Temozolomide—melanoma	0.00088	0.00249	CcSEcCtD
Dicyclomine—Nausea—Carmustine—melanoma	0.000864	0.00244	CcSEcCtD
Dicyclomine—Insomnia—Docetaxel—melanoma	0.000845	0.00239	CcSEcCtD
Dicyclomine—Paraesthesia—Docetaxel—melanoma	0.000839	0.00237	CcSEcCtD
Dicyclomine—Nausea—Temozolomide—melanoma	0.000834	0.00236	CcSEcCtD
Dicyclomine—Dyspnoea—Docetaxel—melanoma	0.000833	0.00236	CcSEcCtD
Dicyclomine—Somnolence—Docetaxel—melanoma	0.000831	0.00235	CcSEcCtD
Dicyclomine—Dyspepsia—Docetaxel—melanoma	0.000822	0.00233	CcSEcCtD
Dicyclomine—Decreased appetite—Docetaxel—melanoma	0.000812	0.0023	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Docetaxel—melanoma	0.000807	0.00228	CcSEcCtD
Dicyclomine—Fatigue—Docetaxel—melanoma	0.000805	0.00228	CcSEcCtD
Dicyclomine—Pain—Docetaxel—melanoma	0.000799	0.00226	CcSEcCtD
Dicyclomine—Constipation—Docetaxel—melanoma	0.000799	0.00226	CcSEcCtD
Dicyclomine—Feeling abnormal—Docetaxel—melanoma	0.00077	0.00218	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Docetaxel—melanoma	0.000764	0.00216	CcSEcCtD
Dicyclomine—Abdominal pain—Docetaxel—melanoma	0.000739	0.00209	CcSEcCtD
Dicyclomine—Hypersensitivity—Docetaxel—melanoma	0.000688	0.00195	CcSEcCtD
Dicyclomine—Asthenia—Docetaxel—melanoma	0.00067	0.0019	CcSEcCtD
Dicyclomine—Pruritus—Docetaxel—melanoma	0.000661	0.00187	CcSEcCtD
Dicyclomine—Dizziness—Docetaxel—melanoma	0.000618	0.00175	CcSEcCtD
Dicyclomine—Vomiting—Docetaxel—melanoma	0.000594	0.00168	CcSEcCtD
Dicyclomine—Rash—Docetaxel—melanoma	0.000589	0.00167	CcSEcCtD
Dicyclomine—Dermatitis—Docetaxel—melanoma	0.000589	0.00167	CcSEcCtD
Dicyclomine—Headache—Docetaxel—melanoma	0.000585	0.00166	CcSEcCtD
Dicyclomine—Nausea—Docetaxel—melanoma	0.000555	0.00157	CcSEcCtD
Dicyclomine—CHRM3—Metabolism—PRKCA—melanoma	5.36e-05	0.000223	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ERCC2—melanoma	5.32e-05	0.000221	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SOCS1—melanoma	5.29e-05	0.00022	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAP2K1—melanoma	5.28e-05	0.00022	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—S100B—melanoma	5.27e-05	0.00022	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SOCS1—melanoma	5.27e-05	0.00022	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAP2K1—melanoma	5.26e-05	0.000219	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—S100B—melanoma	5.26e-05	0.000219	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CD—melanoma	5.24e-05	0.000218	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CD—melanoma	5.22e-05	0.000218	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SOCS1—melanoma	5.22e-05	0.000217	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAP2K1—melanoma	5.21e-05	0.000217	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—S100B—melanoma	5.21e-05	0.000217	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CD—melanoma	5.17e-05	0.000216	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB4—melanoma	5.04e-05	0.00021	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CB—melanoma	5.03e-05	0.00021	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB4—melanoma	5.03e-05	0.000209	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CB—melanoma	5.01e-05	0.000209	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN2B—melanoma	5e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN2B—melanoma	4.98e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB4—melanoma	4.98e-05	0.000207	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CB—melanoma	4.97e-05	0.000207	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.96e-05	0.000207	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN2B—melanoma	4.94e-05	0.000206	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD86—melanoma	4.84e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL8—melanoma	4.83e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD86—melanoma	4.82e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL8—melanoma	4.82e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EDN1—melanoma	4.8e-05	0.0002	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EDN1—melanoma	4.78e-05	0.000199	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD86—melanoma	4.77e-05	0.000199	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL8—melanoma	4.77e-05	0.000199	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EDN1—melanoma	4.74e-05	0.000197	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CSF2—melanoma	4.69e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF1—melanoma	4.69e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF1—melanoma	4.67e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CSF2—melanoma	4.67e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF1—melanoma	4.63e-05	0.000193	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CSF2—melanoma	4.63e-05	0.000193	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ABCB1—melanoma	4.63e-05	0.000193	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—melanoma	4.62e-05	0.000192	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—melanoma	4.6e-05	0.000192	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—E2F1—melanoma	4.59e-05	0.000191	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—E2F1—melanoma	4.57e-05	0.000191	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—melanoma	4.57e-05	0.00019	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—melanoma	4.56e-05	0.00019	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—melanoma	4.55e-05	0.00019	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDGFRA—melanoma	4.54e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—E2F1—melanoma	4.53e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDGFRA—melanoma	4.53e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—melanoma	4.51e-05	0.000188	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ITGB3—melanoma	4.5e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PRKCA—melanoma	4.5e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDGFRA—melanoma	4.48e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PRKCA—melanoma	4.48e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ITGB3—melanoma	4.48e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ITGB3—melanoma	4.44e-05	0.000185	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PRKCA—melanoma	4.44e-05	0.000185	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SPP1—melanoma	4.41e-05	0.000184	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAP2K2—melanoma	4.4e-05	0.000183	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SPP1—melanoma	4.4e-05	0.000183	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL8—melanoma	4.39e-05	0.000183	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAP2K2—melanoma	4.38e-05	0.000183	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL8—melanoma	4.38e-05	0.000182	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SPP1—melanoma	4.35e-05	0.000181	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAP2K2—melanoma	4.34e-05	0.000181	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL8—melanoma	4.33e-05	0.000181	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PRKCA—melanoma	4.26e-05	0.000177	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ERCC2—melanoma	4.22e-05	0.000176	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—melanoma	4.2e-05	0.000175	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—melanoma	4.2e-05	0.000175	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—melanoma	4.18e-05	0.000174	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—melanoma	4.18e-05	0.000174	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RAC1—melanoma	4.17e-05	0.000174	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—melanoma	4.17e-05	0.000174	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RAC1—melanoma	4.15e-05	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—melanoma	4.14e-05	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—melanoma	4.13e-05	0.000172	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RAC1—melanoma	4.11e-05	0.000171	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PPARG—melanoma	4.05e-05	0.000169	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—melanoma	4e-05	0.000167	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—melanoma	3.98e-05	0.000166	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—melanoma	3.95e-05	0.000164	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—melanoma	3.82e-05	0.000159	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—melanoma	3.81e-05	0.000159	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—melanoma	3.77e-05	0.000157	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—melanoma	3.69e-05	0.000154	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FN1—melanoma	3.68e-05	0.000153	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FN1—melanoma	3.67e-05	0.000153	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALB—melanoma	3.64e-05	0.000152	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FN1—melanoma	3.63e-05	0.000151	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH1—melanoma	3.6e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH1—melanoma	3.59e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH1—melanoma	3.55e-05	0.000148	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD80—melanoma	3.53e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APC—melanoma	3.52e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—melanoma	3.52e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KIT—melanoma	3.52e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—NRAS—melanoma	3.52e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD80—melanoma	3.52e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—melanoma	3.51e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KIT—melanoma	3.51e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APC—melanoma	3.51e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—NRAS—melanoma	3.51e-05	0.000146	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.5e-05	0.000146	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD80—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGF—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KIT—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APC—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—NRAS—melanoma	3.48e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGF—melanoma	3.47e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGF—melanoma	3.44e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK3—melanoma	3.37e-05	0.000141	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK3—melanoma	3.36e-05	0.00014	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—melanoma	3.34e-05	0.000139	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK3—melanoma	3.33e-05	0.000139	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BRAF—melanoma	3.31e-05	0.000138	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BRAF—melanoma	3.3e-05	0.000137	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BRAF—melanoma	3.27e-05	0.000136	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IGF1—melanoma	3.22e-05	0.000134	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PPARG—melanoma	3.22e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—melanoma	3.22e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IGF1—melanoma	3.21e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK1—melanoma	3.21e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—melanoma	3.21e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK1—melanoma	3.2e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—melanoma	3.2e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—melanoma	3.19e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IGF1—melanoma	3.18e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK1—melanoma	3.17e-05	0.000132	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—melanoma	3.17e-05	0.000132	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAP2K1—melanoma	3.12e-05	0.00013	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAP2K1—melanoma	3.11e-05	0.000129	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—melanoma	3.1e-05	0.000129	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—melanoma	3.09e-05	0.000129	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAP2K1—melanoma	3.08e-05	0.000128	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	3.07e-05	0.000128	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	3.06e-05	0.000127	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—melanoma	3.06e-05	0.000127	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—melanoma	3.03e-05	0.000126	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	3.03e-05	0.000126	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—melanoma	3.02e-05	0.000126	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—melanoma	2.99e-05	0.000125	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF2—melanoma	2.96e-05	0.000123	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF2—melanoma	2.95e-05	0.000123	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—melanoma	2.93e-05	0.000122	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF2—melanoma	2.93e-05	0.000122	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALB—melanoma	2.89e-05	0.000121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	2.78e-05	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—melanoma	2.78e-05	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—melanoma	2.78e-05	0.000116	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MDM2—melanoma	2.77e-05	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MDM2—melanoma	2.76e-05	0.000115	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—melanoma	2.75e-05	0.000115	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MDM2—melanoma	2.74e-05	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB2—melanoma	2.73e-05	0.000114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB2—melanoma	2.73e-05	0.000114	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB2—melanoma	2.7e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—melanoma	2.7e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—melanoma	2.69e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—melanoma	2.66e-05	0.000111	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL8—melanoma	2.59e-05	0.000108	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL8—melanoma	2.58e-05	0.000108	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRAS—melanoma	2.58e-05	0.000107	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRAS—melanoma	2.57e-05	0.000107	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL8—melanoma	2.56e-05	0.000107	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—melanoma	2.56e-05	0.000106	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRAS—melanoma	2.54e-05	0.000106	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1B—melanoma	2.53e-05	0.000106	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—melanoma	2.53e-05	0.000105	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1B—melanoma	2.52e-05	0.000105	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—melanoma	2.51e-05	0.000104	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1B—melanoma	2.5e-05	0.000104	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—melanoma	2.5e-05	0.000104	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—melanoma	2.48e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—melanoma	2.48e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—melanoma	2.47e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—melanoma	2.47e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—melanoma	2.47e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—melanoma	2.47e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—melanoma	2.46e-05	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—melanoma	2.45e-05	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—melanoma	2.45e-05	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—melanoma	2.43e-05	0.000101	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—melanoma	2.42e-05	0.000101	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—melanoma	2.41e-05	0.0001	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CTNNB1—melanoma	2.39e-05	9.97e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—melanoma	2.38e-05	9.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CTNNB1—melanoma	2.38e-05	9.94e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CTNNB1—melanoma	2.36e-05	9.84e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—melanoma	2.35e-05	9.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—melanoma	2.34e-05	9.74e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—melanoma	2.34e-05	9.74e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—melanoma	2.33e-05	9.71e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—melanoma	2.33e-05	9.71e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—melanoma	2.32e-05	9.68e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NFKB1—melanoma	2.32e-05	9.67e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—melanoma	2.32e-05	9.65e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NFKB1—melanoma	2.31e-05	9.64e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—melanoma	2.31e-05	9.61e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—melanoma	2.3e-05	9.59e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NFKB1—melanoma	2.29e-05	9.54e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—melanoma	2.27e-05	9.48e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—melanoma	2.27e-05	9.45e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—melanoma	2.25e-05	9.36e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—melanoma	2.21e-05	9.2e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—melanoma	2.11e-05	8.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—melanoma	2.1e-05	8.75e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—melanoma	2.09e-05	8.69e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NRAS—melanoma	2.08e-05	8.67e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—melanoma	2.08e-05	8.66e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—melanoma	2.08e-05	8.66e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NRAS—melanoma	2.07e-05	8.64e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—melanoma	2.06e-05	8.58e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NRAS—melanoma	2.05e-05	8.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK3—melanoma	1.99e-05	8.3e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK3—melanoma	1.99e-05	8.27e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK3—melanoma	1.97e-05	8.19e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—melanoma	1.96e-05	8.17e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—melanoma	1.94e-05	8.07e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—melanoma	1.93e-05	8.05e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—melanoma	1.91e-05	7.97e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK1—melanoma	1.9e-05	7.9e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—melanoma	1.9e-05	7.9e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK1—melanoma	1.89e-05	7.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—melanoma	1.89e-05	7.87e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK1—melanoma	1.87e-05	7.8e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—melanoma	1.87e-05	7.79e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—melanoma	1.79e-05	7.46e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—melanoma	1.78e-05	7.44e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—melanoma	1.77e-05	7.36e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—melanoma	1.64e-05	6.85e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—melanoma	1.64e-05	6.83e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—melanoma	1.62e-05	6.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—melanoma	1.6e-05	6.67e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—melanoma	1.59e-05	6.63e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—melanoma	1.59e-05	6.61e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—melanoma	1.57e-05	6.54e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—melanoma	1.56e-05	6.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRAS—melanoma	1.52e-05	6.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRAS—melanoma	1.52e-05	6.32e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRAS—melanoma	1.5e-05	6.26e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—melanoma	1.46e-05	6.07e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—melanoma	1.45e-05	6.05e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—melanoma	1.44e-05	5.99e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—melanoma	1.34e-05	5.6e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—melanoma	1.34e-05	5.58e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—melanoma	1.33e-05	5.53e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—melanoma	1.27e-05	5.3e-05	CbGpPWpGaD
